Professional Bio
Frederick S. Ling, M.D. is an Associate Professor of medicine in the Cardiology Unit and Director of the Cardiac Catheterization Laboratory. He joined the faculty in 1993 after training at Yale University in both cardiovascular medicine and interventional cardiology. Dr. Ling specializes in all aspects of interventional cardiology in the evaluation and treatment of coronary artery disease.
Under his direction, the Cardiac Catheterization Laboratory currently consists of four labs, but is undergoing expansion. All angiographic studies are now digitally archived and networked for immediate access and review.
A computerized reporting system with a central database tracks patients for data collection and research. The Cardiac Catheterization Laboratory also has been at the core of Strong Memorial Hospital's successful clinical program to treat acute myocardial infarction by primary angioplasty or stenting.
Education / Certification
M.D., New York University School of Medicine 1986
Resident, Beth Israel Hospital 1986-89
Clinical Fellow, Yale-New Haven Hospital 1989-91
Research Fellow, Yale-New Haven Hospital 1991-1992
Fellow, Yale-New Haven Hospital 1992-1993
Research and Professional Experience
University of Rochester School of Medicine and Dentistry, Assistant Professor of Medicine/Cardiology 1993-2000
University of Rochester School of Medicine and Dentistry, Associate Professor of Medicine/Cardiology 2000-Present
2007
Nguyen, N, Hasan, S; Caufield, L; Ling, FS; Narins, CR. "Randomized Controlled Trial of Topical Memostasis Pad Use for Achieving Vascular Memostasis Following Percutaneous Coronary Intervention". Cathet Cardiovasc Interventi. 2007; : 801-807. |
2007
Le MQ; Ling FS. "Spontaneous dissection of the left amin coronary artery treated with percutaneous coronary stenting." J Inv Cardiol. 2007; 19(8): E218-221. |
2006 Sep 7
Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR, . "Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention." The New England journal of medicine. 2006 Sep 7; 355(10):1006-17. |
2006 Jun
Narins CR, Ling FS, Fischi M, Peterson DR, Bausch J, Zareba W. "In-hospital mortality among women undergoing contemporary elective percutaneous coronary intervention: a reexamination of the gender gap." Clinical cardiology. 2006 Jun 0; 29(6):254-8. |
2006
Nissen SE, Tuzcu EM, Brewer B et al. for the ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators. "Effect of ACAT inhibitation on the progression of atherosclerosis." N Engl J Med. 2006; : 1253-1263. |
